On May 16, 2018 Pfizer Inc. reported that new data from its diversified portfolio of marketed and investigational oncology medicines will be presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) in Chicago from June 1-5, 2018 (Press release, Pfizer, MAY 16, 2018, View Source [SID1234526724]). Data from programs in small molecules, immunotherapies, biomarker-driven medicines, as well as biosimilars, will be featured in more than 40 abstracts, including company-sponsored and collaborative research studies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The breadth and depth of our data at ASCO (Free ASCO Whitepaper) this year are indicative of our focus on understanding the full potential of our medicines, including IBRANCE and XTANDI, which are already making a difference in patient lives. We are also exploring new and exciting pathways designed to transform treatment outcomes"

Tweet this
"The breadth and depth of our data at ASCO (Free ASCO Whitepaper) this year are indicative of our focus on understanding the full potential of our medicines, including IBRANCE and XTANDI, which are already making a difference in patient lives. We are also exploring new and exciting pathways designed to transform treatment outcomes," said Charles Hugh-Jones, MD, FRCP, chief medical officer, Pfizer Oncology. "Our comprehensive research is resulting in near-term potential benefits for patients, as well as multiple new therapies that we hope to introduce this year."

The research to be presented includes new insights on Pfizer’s late-phase investigational compounds dacomitinib, lorlatinib, talazoparib and glasdegib, as well as Pfizer’s marketed therapy XTANDI (enzalutamide). These compounds represent the next five potential Pfizer Oncology advancements in lung, breast, hematologic and prostate cancers.

"At this year’s ASCO (Free ASCO Whitepaper), we’re particularly excited to present overall survival data for dacomitinib that builds upon our precision medicine focus and legacy in lung cancer," said Mace Rothenberg, MD, chief development officer, Oncology, Pfizer Global Product Development. "Further, we’ll be sharing new insights on our medicines across 16 disease areas and 13 mechanisms of action, including early-phase through post-approval analyses. Our extensive presence reinforces our commitment to speeding accessible breakthrough medicines to patients."

Key Pfizer abstracts include:

The first presentation of final overall survival results from the pivotal ARCHER 1050 study of dacomitinib vs. gefitinib in locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutation
Phase 2 results from a clinical research collaboration evaluating IBRANCE (palbociclib) in combination with cetuximab in platinum-resistant HPV unrelated recurrent/metastatic head and neck squamous cell carcinoma
An analysis of resistance to therapy based on genetic mutations from the pivotal PALOMA-3 trial of CDK 4/6 inhibitor IBRANCE in combination with fulvestrant in ER+/HER2- metastatic breast cancer
Longer-term efficacy and safety results from two registrational trials: the JAVELIN Merkel 200 study of PD-L1 inhibitor BAVENCIO (avelumab) in a rare skin cancer, being developed in collaboration with Merck KGaA, Darmstadt, Germany and the BFORE trial of BOSULIF (bosutinib) vs. imatinib in patients with newly diagnosed chronic myeloid leukemia
A comparative clinical study of PF-06439535, a candidate bevacizumab biosimilar, and reference bevacizumab, in patients with advanced non-squamous non-small cell lung cancer
Details for the Pfizer-sponsored oral presentations are below:

Title/Abstract Number Date/Time (CDT) Location
(Abstract 9008) Friday, June 1 Hall D1
Avelumab (anti-PD-L1) in Combination with Crizotinib or Lorlatinib in Patients with Previously Treated Advanced NSCLC: Phase 1b Results from JAVELIN Lung 101 4:30 PM – 6:00 PM

Shaw A
(Abstract 7002) Saturday, June 2 E450
Bosutinib vs Imatinib for Newly Diagnosed Chronic Myeloid Leukemia in the BFORE Trial: 24-Month Follow-Up 3:00 PM – 6:00 PM

Cortes J
(Abstract 1001) Sunday, June 3 Hall D2
Genetic Landscape of Resistance to CDK4/6 Inhibition in Circulating Tumor DNA (ctDNA) Analysis of the PALOMA3 Trial of Palbociclib and Fulvestrant Versus Placebo and Fulvestrant 8:00 AM – 11:00 AM

Turner N
(Abstract 6008) Sunday, June 3 E451
Multicenter Phase 2 Trial of Palbociclib, a Selective Cyclin Dependent Kinase (CDK) 4/6 Inhibitor, and Cetuximab in Platinum-Resistant HPV Unrelated (-) Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC)

8:00 AM – 11:00 AM

Adkins D
(Abstract 9507) Monday, June 4
Arie Crown Theater

Two-Year Efficacy and Safety Update from JAVELIN Merkel 200 Part A: A Registrational Study of Avelumab in Metastatic Merkel Cell Carcinoma Progressed on Chemotherapy 8:00 AM – 11:00 AM

Nghiem P
(Abstract 109) Monday, June 4 Hall D1
A Comparative Clinical Study of PF-06439535, a Candidate Bevacizumab Biosimilar, and Reference Bevacizumab, in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer 9:45 AM – 11:15 AM

Socinski M
(Abstract 9004) Monday, June 4 Hall B1
Dacomitinib (daco) Versus Gefitinib (gef) for First-Line Treatment of Advanced NSCLC (ARCHER 1050): Final Overall Survival (OS) Analysis 3:00 PM – 6:00 PM

Mok T

Please see a complete list of Pfizer-sponsored abstracts featuring data on our broad pipeline of biologics and small molecules at View Source

Learn more about how developing new medicines and supporting people with cancer is personal for Pfizer Oncology at View Source

Dacomitinib, lorlatinib, talazoparib and glasdegib are investigational agents and have not been approved by any regulatory agencies.